

Index

A

- Acquired resistance
 - BRAF(V600E), 103
 - CDK inhibitors, 200, 201
 - c-Jun/ECM/FAK/Src, 107
 - COT, 104
 - crizotinib, 40
 - DUSPs, 105
 - EGFR-specific TKIs, 39
 - erlotinib/gefitinib, 42
 - feedback loops, 105
 - first-generation EGFR inhibitors, 38, 39
 - IGF1R, 104
 - MEK inhibitors, 104, 106
 - osimertinib, 43
 - PDGFR β , 104
 - RAF inhibition, 103, 106
 - RTKs and BRAF, 40
 - SOX10, 104
 - TKI, 37
- Adenosine monophosphate (AMP), 57
- Ado-trastuzumab emtansine (T-DM1), 59–60
- Anaplastic lymphoma kinase (ALK)
 - non-dominant resistance, 40
 - resistance, 40–42
- Angiogenesis
 - bevacizumab, 213
 - tumor progression, 212
 - VEGF, 212, 213
- Anti-angiogenic drugs
 - afibercept, 216, 223
 - bevacizumab, 216, 223
 - chemotherapy, 216
 - clinical benefits, 214–215
 - cytotoxic therapy, 224
 - VEGF, 225
- Anti-angiogenic therapies, 212, 221
 - acquired and intrinsic resistance, 217
 - angiogenic pathways, 218, 219
 - bevacizumab, 223
 - BMDC, 219, 220, 224
 - CAFs, 221
 - glioblastomas, 223
 - hypoxia, 225
 - immature myeloid cells, 220
 - immunotherapy, 225
 - pericyte, 220, 221
 - PFS and OS, 217
 - preclinical studies, 224
 - resistance mechanisms, 218
 - sunitinib, 222, 223
 - TAMs, 220, 225
 - TEMs, 220
 - tumor growth, 222
 - vascularization (*see* Vascularization mechanisms)
 - VEGF, 223, 225
- Antibody-drug conjugate (ADC), 59
- Antibody-mediated cellular toxicity (ADCC), 54
- Anti-EGFR antibodies
 - biomarkers of resistance, 12
 - BRAF blockade, 9
 - clinical use, 8
 - CRC, 3
 - HER2, 11
 - KRAS mutation, 9
 - mCRC, 5, 10, 16
 - MET amplification, 13

- Anti-EGFR antibodies (*cont.*)
 - NRAS mutation, 9
 - PIK3CA exon 20 mutations, 10
 - resistance, 15
 - RTKs, 3
 - therapy, 8, 11, 13, 16
- Anti-HGF mAbs
 - ficlatuzumab, 73
 - rilotumumab (AMG102, Amgen), 72
 - TAK-701, 73
- Anti-MET mAbs
 - emibetuzumab, 73
 - onartuzumab, 73
- Apoptosis
 - blocks
 - chemotherapeutic regimens, 152
 - kinase inhibitors, 152
 - Myc-induced tumorigenesis, 151
 - prominent pro-apoptotic BCL-2 family member, 150
 - BIM* deletion polymorphism, 153
 - direct activation model, 150
 - indirect activation model, 150
 - and proliferation, 148
 - PTEN-negative IHC staining, 154
 - receptor-tyrosine kinases, 153
 - robust apoptotic response, 153
 - unified model, 150
- B**
- Basal-like breast cancer (BLBC), 191
- B cell-lymphoma 2 (BCL-2)
 - family members, 161–162
 - inhibitors, 156–157
- BCL-2/BCL-xL dual inhibitors, 154–155
- Bevacizumab, 213, 217
- BH3 mimetics, 150, 157–158, 161–164
 - anti-proliferative and anti-survival signaling, 148
 - apoptosis (*see* Apoptosis)
 - BCL-2/BCL-xL dual inhibitors, 154–155
 - binding patterns interactions, 152
 - in cancer, 149
 - CLL, 152
 - dynamic BH3 profiling, 153
 - KRAS mutant lung cancers, 153
 - mitochondria, 148
 - mitochondrial membrane permeabilization, 152 (*see also* Navitoclax)
 - resistance (*see* Resistance)
 - SCLC, 152
 - specificity and non-specificity, 154
 - toxic stimuli, 152
 - treatment regimens, 153
 - venetoclax (*see* Venetoclax)
- BIM* deletion polymorphism, 153
- Bioluminescence resonance energy transfer (BRET), 155
- Bone marrow-derived cells (BMDCs), 216, 219, 220
- BRAF-mutated melanoma, 90, 92, 93, 95, 102–105, 107
- Breast cancer, 53–57
 - HER2, 53
 - IGF-1R, 57
 - PTEN deficiency, 55
 - trastuzumab (*see* Trastuzumab)
- Bruton tyrosine kinase (BTK) inhibitor, 166
- C**
- Cancer
 - HGF/MET axis
 - adult and pediatric glioblastomas, 71
 - deregulated MET activation, 70
 - progression and metastasis, 70
 - signaling, 70
 - spliced receptor, 71
 - PI3K/AKT
 - AKT1E17K mutation, 125
 - AKT/mTOR signaling, 124
 - helical and kinase domains, 124
 - HER2 overexpression, 124
 - PTEN/INPP4B lipid phosphatases, 125
 - rapalogs/mTOR catalytic inhibitors, 125
 - valid (and rational) therapeutic strategy, 124
- Cancer-associated fibroblasts (CAFs), 221
- Carboxy terminal fragment (CTF), 54
- CDK-activating kinase (CAK), 184
- CDK1/2 activation, 202–203
- CDK2-dependent cancers, 192, 193
- CDK2 inhibitors, 195, 196
- CDK4/6-dependent cancers, 192, 193
- CDK4/6 inhibitors, 197
 - abemaciclib, 195
 - MAPK pathway, 199
 - MONALEESA-2 trial, 195
 - palbociclib, 194
 - PALOMA-1 trial, 194
 - PI3K-AKT-mTOR pathway, 198, 199
- CDKi resistance, 198
- Cell-endogenous CDK inhibitors, 187–188
- Chemotherapy, 107, 216, 224
- Chronic lymphocytic leukemia (CLL), 152
- Circulating tumor DNA (ctDNA), 8, 9, 15, 16
- Colorectal cancer (CRC), 213

- BRAF mutations, 9
- EGFR, 2
- HER2 amplification, 12
- HER3* mutations, 12
- KRAS mutations in exon 2, 8
- mCRC, 2
- MEK, 9
- MET amplification, 12, 13
- PIK3CA*-mutant, 11
- resistance, 5
- Crizotinib, 40
- Cyclin-dependent kinase 4 and 6, 186, 187
 - See also* Cyclin-dependent kinases (CDKs)
- Cyclin-dependent kinases (CDKs)
 - acquired resistance, 200, 201
 - animal models, 185
 - ATP-binding site, 184
 - cdc28*, 184
 - CDK-cyclin-RB-E2F axis, 191
 - CDK1/2/4/6, 184
 - CDK2-dependent cancers, 192, 193
 - CDK2 inhibitors, 195, 196
 - CDK4/6-dependent cancers, 192, 193
 - CDK4/6 inhibitors, 186, 193–195
 - CDK7, 184
 - CDKi resistance, 198
 - cell cycle, 182, 183, 186
 - cell-endogenous CDK inhibitors, 187, 188
 - cytotoxic agents, 197
 - ER-positive breast cancer, 183
 - G1 arrest, 197
 - MAPK pathway, 188–190, 199
 - mechanisms of resistance, 196
 - PI3K-AKT-mTOR pathway, 198, 199
 - senescence, 196
 - signaling pathways, 189
 - small molecule, 193
 - WEE1 inhibitors, 184
 - yeast, 183, 186, 187
- Cyclin E1 (CCNE1) gene, 201, 202
- Cytoplasmic tyrosine kinase domain, 40
- Cytotoxic chemotherapy, 216

- D**
- Drug-induced resistance, 95
- Drug resistance, 14–15, 36, 198
- Dual specificity protein phosphatases (DUSPs), 105
- Dynamic BH3 profiling technique, 153

- E**
- 4E-binding protein 1 (4EBP1), 123
- E2F transcription factor, 189
- Epidermal growth factor receptor (EGFR), 70
 - anti-EGFR therapy, 11, 13
 - biomarkers, 3
 - BRAF inactivation, 9
 - cell-free DNA analysis, 14
 - chronic intestinal inflammation, 3
 - combination therapies, 9
 - CRC, 2, 3
 - cytotoxic chemotherapy, 2
 - downstream effectors, 4
 - homo- and hetero-dimerization, 3
 - inflammatory stimuli, 3
 - inhibition, 4
 - kinase inhibition, 14
 - ligands, 15
 - MET tyrosine kinase receptor, 12
 - RAS family, 8
 - resistance, 10, 14, 40–42
 - RTKs, 3
 - S492R, G465E and G465R mutations, 14
 - signal transducer, 5
 - signaling pathways, 4
 - tumorgrafts, 14
 - tyrosine kinase inhibitors, 12
- ER-positive breast cancer, 192
- Eukaryotic initiation factor 4E (eIF4E), 124
- Extracellular domain (ECD), 54
- Extracellular signal regulated kinase (ERK)
 - cascade, 103
 - acquired resistance (*see* Acquired resistance)
 - BRAF inhibitors, 91
 - cancer, 90–92, 103, 108
 - drug-induced resistance, 95
 - ERK inhibitors, 94
 - intrinsic resistance, 95, 101–103
 - MEK inhibitors, 93, 94
 - paradoxical activation, 95, 96
 - RAF inhibitors, 92, 93
 - RAFTs, 90
 - RAS activation, 90
 - targeted cancer therapy, 92

- F**
- First-generation EGFR kinase inhibitors, 38
- Flavopiridol, 200
- FOXM1, 190

- G**
- Genomics of drug sensitivity in cancer (GDSC), 155
- Glioblastoma multiforme (GBM), 191, 213
- Glioblastomas, 223

H

- Hepatocyte growth factor (HGF), 12, 57, 102
 - See also* MET/HGF axis
- HGF, *see* Hepatocyte growth factor (HGF)
- HGF/MET axis
 - advantages and disadvantages, 71
 - and cancer, 70–71
 - monoclonal antibodies, 71
 - TKIs/mAbs, 71
- High-grade serous ovarian cancers (HGSC), 191
- Histone deacetylase (HDAC) inhibitors, 137
- Hormone receptor-dependent resistance, 133–134
- Human epidermal growth factor receptor 2 (HER2), 11–12

I

- Immunohistochemistry (IHC) analysis, 54
- Immunotherapy, 108, 225
- Insulin growth factor-1/2 (IGF-1/2), 57
- Insulin-like growth factor receptor 1 (IGF-1R), 57, 104
- Intratumor heterogeneity, 35
- Intrinsic resistance
 - anti-cancer drugs, 102
 - ATP-competitive inhibitors, 101
 - BRAF inhibitors, 103
 - EGFR, 103
 - HGF, 102
 - paradoxical ERK activation, 101
 - RAF
 - and EGFR inhibition, 102
 - inhibitors, 101
 - and MEK inhibitors, 101
 - SFKs, 102
 - vemurafenib, 102

J

- Janus kinase/signal transducers and activators of transcription (JAK/STAT) pathways, 52, 119

K

- Kinase inhibitors, 32–33
- Kinase specific inhibitors, 92, 94, 105
- Kinase switch, 78

L

- Lapatinib, 58
- Lorlatinib, 42

Lung cancer

- classes of patient resistance, 36–38
- clonal dynamism, 35
- histological types, 31
- oncogenic drivers, 34
- tobacco smoking, 30

M

- MCL-1 inhibitors, 158–161
 - and navitoclax, 164–165
 - and venetoclax, 166
- Melanomas, 2
- MET, 12–13
- Metastatic colorectal cancer (mCRC), 3–14
 - anti-EGFR antibodies (*see* Anti-EGFR antibodies)
 - anti-EGFR moAbs, 3
 - BRAF-mutant, 13
 - cetuximab and panitumumab, 2
 - trastuzumab-lapatinib, 12
- MET/HGF axis
 - invasive growth, 68
 - ligand binding, 68
 - reciprocal trans-phosphorylation, 70
 - RTKs, 70
 - tumor progression, 69
- MET-targeted therapies
 - amplification, 77
 - downstream transducers activation, 77–78
 - in vitro and preclinical models, 68, 75 (*see also* MET/HGF axis)
 - mutations, drug interactions, 75–77
 - parallel compensatory pathways, 78–79
 - selective TKIs, 68
 - TKIs mechanisms, 75
- Mitogen-activated protein kinase (MAPK), 53, 56–58, 70, 119, 188–190, 199
- Mitogen-activated protein kinase kinase (MEK)
 - downstream effector, 9
 - inhibitors, 93, 94
 - RAS family, 8
 - targeting downstream effectors, 8
- Monoclonal antibodies (moAbs), 2, 36, 71
- Murine double minute 2 (MDM2), 55
- Myeloid-derived suppressor cells (MDSCs), 220

N

- Navitoclax
 - acquired resistance, 156
 - BCL-2 specific inhibitors, 156–157
 - clinical trial correlatives, 156

- in vitro correlation, 155
 - and MCL-1 inhibition, 164–165
- Neratinib, 59
- Neuroblastoma RAS viral oncogene homolog (NRAS), 8, 9
- Non-BH3 mimetic MCL-1 inhibitors, 160–161
- Non-small cell lung cancers (NSCLCs), 2, 153, 213
- N-terminal adaptor-binding domain (ABD), 120
- Nuclear translocation signal (NTS), 108

- P**
- Palbociclib, 194, 197, 198
- Palbociclib-resistant cells, 200
- Paradoxical effects, 96
- Parallel compensatory pathways, 38
- Pericytes, 220, 221
- Pertuzumab, 58
- Phosphatase and tensin homologue (PTEN), 54, 55
- Phosphatidylinositol 3-kinase (PI3K), 119
- Phosphatidylinositol-3,4,5-trisphosphate (PIP₃), 55
- Phosphatidylinositol-4,5-bisphosphate (PIP₂), 54
- PI3K/AKT/mTOR inhibitors, 198, 199
 - advantages, 136
 - bromodomain and BET proteins, 137
 - drug delivery, 136
 - epigenome, 137
 - HDAC inhibitors, 137
 - hormone receptor-dependent resistance, 133–134
 - isoforms dependency, 129–130
 - pharmacological stress, 127
 - resistance, 127–129
 - Ser/Thr kinases, 130–133
 - transcription factors, 135–136
- PI3K/AKT pathway
 - inhibitors
 - BEZ235 (Novartis Pharmaceuticals), 125
 - BKM120, 126
 - BYL719, 126
 - CAL-101, 126
 - catalytic and allosteric, 126
 - GDC-0032, 126
 - GDC-0941, 126
 - mTORC1, 127
 - See also* Cancer
- PI3K-AKT-PTEN pathway, 10–11
- PI3K enzymes
 - C2 domain, 120
 - class I, II and III, 119
 - crystal structure, 120
 - defined, 120
 - helical domain, 120
 - kinase domain, 120
 - p85-binding domain, 120
 - Pik3ca* knock-out mice, 121
 - RBD, 120
 - SH2 domains, 120
 - signal transduction, 121–124
- Platelet derived growth factor receptor beta (PDGFRβ), 104
- Pro-angiogenic factors, 219
- Protein-based anti-angiogenic drugs, 216
- Protein kinase
 - inhibitor, 36
 - ribosomal, 130
 - serine/threonine, 123
- Protein-protein interaction (PPI), 154

- R**
- Ramucirumab, 216
- Rapidly accelerated fibrosarcoma (RAF) inhibitors, 92, 93
- RAS, 8–9
- Ras-binding domain (RBD), 120
- Receptor tyrosine kinases (RTKs), 3, 52, 56, 57, 95, 96, 119, 188, 201
 - downstream signal transduction, 119
 - PI3K family (*see* PI3K enzymes)
 - signaling pathways, 119
- Renal cell carcinoma (RCC), 213
- Replication stress, 77
- Resistance
 - BIM* deletion polymorphism positive patients, 164
 - growth factor
 - pathway regulation, 161–162
 - and survival signaling pathways, 162
 - histone deacetylase inhibitors, 164
 - robust apoptotic response, 162
 - strategies, 162
- Response rates (RRs), 9
- Retinoblastoma (RB) deficiency, 201

- S**
- Senescence, 197
- Ser/Thr kinases, 130–133
- Sex determining region Y-box 10 (SOX10), 104
- Signal transducer and activator of transcription (STAT), 52
- Signal transducer and activator of transcription-3 (STAT3), 56

Small cell lung cancer (SCLC), 152
Small kinase inhibitors, 74
SNS032, 193
SRC-family kinase (SFK), 102
Sunitinib, 216

T

Targeted therapies
 anti-apoptotic members, 160
 (*see also* Apoptosis)
 cancer cells, 135
 cellular processes, 130
 growth factor/survival signaling
 pathways, 162
 KRAS mutant lung cancers, 153
 progression free survival, 152
 RTKs activation, 127
The Cancer Genome Atlas (TCGA), 191
Therapeutic antibodies, xi
Tie2-expressing monocytes (TEMs), 220
Transcription initiation factor IA (TIF-IA), 124
Trastuzumab
 epitope masking, 55–56
 mechanism of action, 53–54
 mechanism of resistance, 54
 receptor tyrosine kinases, 56–57
 treatment strategies, resistance
 Lapatinib, 58–59
 Neratinib, 59
 Pertuzumab, 58
 T-DM1, 59–60
 upregulation of downstream signaling,
 54–55
Tumor-associated macrophages (TAMs), 220
Tumor heterogeneity, 35
Tumor hypoxia, 218
Tumor lysis syndrome (TLS), 166
Tumor microenvironment, 212, 219, 220,
 224, 225
Tumor necrosis factor α (TNF α), 56
Tyrosine kinase inhibitory (TKI)
 acquired resistance, 37
 ALK-specific, 38, 41
 anti-cancer drugs, 36

ATP competitors, 74
biochemical and crystallization studies, 75
cabozantinib, non-selective oral multi-
 kinase inhibitor, 74
 in cancer therapy, 68
 clinical applications, 37, 38
 de novo and acquired resistance, 68
 drug resistance, 37
 EGFR-specific, 39–41
 HER2-specific, 43
 intracellular target, 37
 lapatinib, 58
 mAbs, 71
 mechanisms, 75
 bypass signaling, 38
 phenotype alterations, 39
 secondary mutations, 38
 MET gene amplification, 78
 molecular targeted cancer drugs, 37
 oncogenic target protein kinase, 38
 resistance, 39, 42
 target kinase domain, 36
 therapy, 42

V

Vascular endothelial growth factor-A
 (VEGF-A), 212
Vascularization mechanisms
 vasculogenic mimicry, 222
 vessel co-option, 221
Vascular normalization, 216
Vasculogenic mimicry, 222
Venetoclax
 acquired resistance, 158
 BTK inhibitor, 166
 in vitro correlatives, 157–158
 in vivo correlatives, 158
 and MCL-1 inhibitors, 158–161, 166
 non-BH3 mimetic MCL-1 inhibitors,
 160–161
 pre-clinical studies, 166
 TLS, 166
V-Raf murine sarcoma viral oncogene
 homolog B1 (BRAF), 9